Drug Development at Siragen Pharmaceuticals
Siragen’s unique drug discovery efforts have been focused on a major molecular enzyme central to both intracellular calcium and core cellular dyshomeostasis. Siragen’s novel target is central to pathways that trigger synaptic dysfunction leading to pathological landmarks of neuro-degenerative disorders. Siragen’s small molecules have been modeled using a structure-guided design, enhancing drastically its specificity. Inhibiting this target modulates upstream events prior to the onset of pathological changes of synapse loss and cell death.
Siragen’s molecules are at the lead optimization stage for Alzheimer’s disease with excellent pharmacokinetic properties, biochemical correction of disease markers of inflammation, synaptic toxicity and behavioral normalization of memory deficits in animal models.
Siragen’s novel drug design approach is also a paradigm shift for creating additional modulators applicable to a number of diseases in which auto-inhibitory dysfunction is the major mechanism of pathophysiology. At least three classes of diseases have been reported to be causally associated with aberrant activity of the target: neuropsychiatric disorders (depression, schizophrenia), metabolic disorders (obesity and diabetes) and cancers (prostate, liver). These other indications support a potential development platform for an expanded therapeutic pipeline.